- Home
- NVX vs CLLS Comparison
NVX vs CLLS Comparison
Compare NVX & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVX
- CLLS
- Stock Information
- Founded
- NVX 2012
- CLLS 1999
- Country
- NVX Australia
- CLLS France
- Employees
- NVX N/A
- CLLS N/A
- Industry
- NVX Industrial Machinery/Components
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- NVX Miscellaneous
- CLLS Health Care
- Exchange
- NVX Nasdaq
- CLLS Nasdaq
- Market Cap
- NVX 232.1M
- CLLS 240.2M
- IPO Year
- NVX N/A
- CLLS 2007
- Fundamental
- Price
- NVX $1.92
- CLLS $1.86
- Analyst Decision
- NVX Strong Buy
- CLLS Buy
- Analyst Count
- NVX 1
- CLLS 3
- Target Price
- NVX $4.00
- CLLS $7.00
- AVG Volume (30 Days)
- NVX 57.6K
- CLLS 90.3K
- Earning Date
- NVX 01-01-0001
- CLLS 11-04-2024
- Dividend Yield
- NVX N/A
- CLLS N/A
- EPS Growth
- NVX N/A
- CLLS N/A
- EPS
- NVX N/A
- CLLS N/A
- Revenue
- NVX $6,875,112.00
- CLLS $36,042,000.00
- Revenue This Year
- NVX $89.31
- CLLS $271.02
- Revenue Next Year
- NVX $410.89
- CLLS $33.48
- P/E Ratio
- NVX N/A
- CLLS N/A
- Revenue Growth
- NVX 19.05
- CLLS 46.96
- 52 Week Low
- NVX $1.40
- CLLS $1.70
- 52 Week High
- NVX $3.10
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- NVX 47.04
- CLLS 46.46
- Support Level
- NVX $1.96
- CLLS $1.77
- Resistance Level
- NVX $2.11
- CLLS $1.98
- Average True Range (ATR)
- NVX 0.12
- CLLS 0.10
- MACD
- NVX -0.01
- CLLS 0.02
- Stochastic Oscillator
- NVX 39.34
- CLLS 53.37
About NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration and Mining, Battery Technology, and NOVONIX Anode Materials. Graphite Exploration and Mining segment is engaged in the exploration and development of high-grade flake graphite deposits. The NOVONIX Anode Materials segment develops and manufactures battery anode materials. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Technology segment generates maximum revenue for the company.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.